Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial - PubMe
3 months ago
- #radiotherapy
- #clinical trial
- #prostate cancer
- The HYPO-RT-PC trial compared ultra-hypofractionated (42.7 Gy in 7 fractions) and conventionally fractionated radiotherapy (78.0 Gy in 39 fractions) for intermediate-to-high-risk localized prostate cancer.
- After a median follow-up of 10.6-10.7 years, ultra-hypofractionated radiotherapy showed non-inferiority with 10-year failure-free survival rates of 72% vs. 65% for conventional fractionation.
- Late grade 2 or worse genitourinary toxic effects were similar between groups (30% conventional vs. 28% ultra-hypofractionated).
- Late grade 2 or worse gastrointestinal toxic effects were also comparable (14% in both groups).
- The study supports ultra-hypofractionated radiotherapy (7 fractions) as a safe, effective, and practical standard-of-care option for intermediate-risk prostate cancer.